BioXgen Seeks Community Investment to Address $9 Billion Post-Operative Atrial Fibrillation Crisis

BioXgen, a medical device company developing a cardiac patch to prevent post-operative atrial fibrillation (POAF), has opened a Community Investment Round under Regulation Crowdfunding (Reg CF). POAF is the most common complication following open-heart surgery, affecting roughly 50% of the 500,000 Americans who undergo such procedures annually, and it increases risks of stroke, recurrent atrial fibrillation, kidney failure, and death. The condition costs the U.S. healthcare system approximately $9 billion each year, with no FDA-cleared device currently available to prevent it, leaving surgeons to rely on off-label pharmaceuticals.

The company's cardiac patch is placed directly on the heart's surface during surgery, and pre-clinical data published in Circulation (Rao et al. / Konhilas, v.136, 2017) shows it reduced POAF rates from about 50% to under 5%, a tenfold improvement. Unpublished data from over 200 additional patients have yielded similar results. BioXgen has completed a Q-submission to the FDA, solidifying a 510(k) regulatory pathway that targets clearance within 18 months if funding needs are met, with the goal of establishing the device as standard care within 36 to 48 months post-approval.

The investment round, hosted by DealMaker Securities, allows retail investors to participate with a minimum investment of $500, breaking from traditional institutional-only funding models. BioXgen emphasizes a lean operational structure, including contracted manufacturing and an intellectual property portfolio designed to accommodate community investors alongside institutional partners. The company's leadership includes Dr. David Skinner, President and CEO, who has prior experience scaling a medical company to a successful exit, and Dr. John P. Konhilas, Chief Science Officer, a physiology professor with over 30 years of research in cardiac disease and therapeutic development, including expertise in regulatory pathways like 510(k).

An upcoming live investor presentation on April 7 will feature Dr. Skinner and Dr. Konhilas discussing the investment opportunity. Registration for the event is available at https://dnagency.lpages.co/bioxgen-investor-presentation/. According to Dr. Skinner, the company has the data, regulatory path, clinical partner, and team experience to address this unmet medical need, offering the public a chance to invest in a solution to a significant healthcare crisis. More details on the offering can be found at https://invest.bioxgen.life/, where BioXgen has filed a Form C with the Securities and Exchange Commission, accessible via the same link.